A new once-daily pill has delivered one of the most significant advances in pancreatic cancer treatment in decades. Researchers reported that the experimental drug daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer whose disease had progressed after initial treatment.
The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal of Medicine. Cancer specialists described the results as potentially practice-changing for a disease that has long had limited treatment options.
The latest pancreatic cancer pill targets KRAS mutations, which drive more than 90% of pancreatic cancers. Scientists had considered these mutations difficult to target for many years, making the success of daraxonrasib particularly important.
Drug Targets A Long-Standing Cancer Challenge
Daraxonrasib belongs to a new class of medicines known as RAS inhibitors. The drug works by blocking cancer-driving mutations that help tumour cells grow and spread throughout the body. Researchers said the treatment slowed disease progression and improved quality of life for many patients.
In the international trial involving about 500 patients with metastatic pancreatic cancer, those who received daraxonrasib lived a median of 13.2 months. Patients who received standard chemotherapy survived a median of 6.6 to 6.7 months. The results represent a major improvement in a cancer known for its poor survival rates.
The study also found fewer serious side effects among patients taking the pill compared with those receiving chemotherapy. About 43.6% of patients on daraxonrasib experienced severe side effects, compared with 57.5% in the chemotherapy group. Only a small percentage stopped treatment because of side effects.
Also Read: Magnitude 4.6 Earthquake Jolts Bay Of Bengal, No Damage Reported
Several oncologists described the results as unprecedented. One cancer expert said she became emotional after seeing the data because patients remained on treatment for longer periods and continued receiving meaningful benefits.
Hope For Patients And Future Research
The US Food and Drug Administration has already granted expanded access to some eligible patients and is expediting its review of the treatment. Researchers are now studying whether the drug can help patients earlier in the disease and whether it can work alongside other therapies.
Pancreatic cancer remains one of the deadliest forms of cancer worldwide. Doctors often detect the disease after it has spread, which limits treatment options. Experts believe the new findings could mark the beginning of a major shift in how advanced pancreatic cancer is treated.
The promising pancreatic cancer pill has generated optimism among researchers and patients alike. While more work remains before widespread approval, many specialists view daraxonrasib as one of the most encouraging developments in pancreatic cancer care in decades.
